2023-07-16 11:27:05
This experimental vaccine might reduce 40% risk of death or recurrence of skin cancer. Lead researcher Dr Jane Healy believes the vaccine might be available from 2028. Earlier this year, scientists announced that an experimental vaccine, prepares the immune system to target cancer cells, and recognizes specific genetic mutations in cancer cells, so it can destroy them if they recur. The researcher behind the trial revealed that a larger study, involving thousands of people, including British patients, should start next year and might allow the NHS to approve the breakthrough vaccine by 2028. Dr Jane Healy, senior oncology researcher at MSD, the pharmaceutical company behind the skin cancer vaccine, said their trial was exciting because it was the first cancer vaccine of its kind to give such good results. The announcement comes a week following the government announced an NHS scheme allowing 10,000 patients to take part in a vaccine trial once morest several types of cancer, led by BioNTech, the maker of the Covid vaccine. Unlike traditional vaccines, new cancer vaccines are not given to prevent disease, but rather to reduce the risk of recurrence in patients recently treated for…
1689515767
#vaccine #skin #cancer
